A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
基本信息
- 批准号:10227996
- 负责人:
- 金额:$ 23.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAgingAmericanAreaAttentionBeliefBenefits and RisksBiologicalBiometryCardiac OutputCardiologyCaringClinical TrialsCommunicationComplexCrossover DesignDataDevelopmentDrug PrescriptionsEFRACEffectivenessElderlyEnsureEnvironmentEventFailureFoundationsFundingFutureGeriatricsGoalsGrantHealthHealth PrioritiesHeartHeart failureImpairmentIndividualInterventionKnowledgeLeadLeftLife ExpectancyManuscriptsMedication ManagementMedicineMentorsMentorshipOffice VisitsOutcomeParticipantPatient Outcomes AssessmentsPatientsPersonal SatisfactionPharmaceutical PreparationsPolypharmacyPopulationPopulation StudyPositioning AttributePrincipal InvestigatorProcessProtocols documentationRandomized Controlled TrialsResearch PersonnelResearch Project GrantsRoleSignal TransductionSyndromeTestingTherapeuticTimeTrainingUncertaintyUnited StatesVariantVentricularaging populationbasecareercareer developmentclinical practicecollegedrug withdrawaleffectiveness implementation studyeffectiveness implementation trialexperienceexperimental studyhospitalization ratesimplementation scienceimprovedimproved outcomeindividual patientinnovationiterative designmortalitymultiple chronic conditionsnovelpatient orientedpreferencepreservationpreventprogramsprototypeshared decision makingskillssuccesssupportive environmenttheoriesworking group
项目摘要
PROJECT SUMMARY
Candidate: My career goal is to improve the wellbeing of older adults with multiple chronic conditions and
polypharmacy by developing and rigorously testing rational strategies to improve medication prescribing
practices; and to become an independent clinician investigator and national leader in Geriatric Cardiology. This
area is particularly relevant for me as a heart failure cardiologist, as I care for older adults who almost
universally have multiple chronic conditions and polypharmacy. My track record as an emerging leader in this
area is evidenced by multiple lead- and senior-author manuscripts, 4 grants as the Principal Investigator
including a GEMSSTAR, my position as the Founding Director of the Weill Cornell Heart Failure with
Preserved Ejection (HFpEF) Program for the Aging, and my role as the Chair of the American College of
Cardiology Geriatric Cardiology Section Early Career Professionals Working Group. Mentors and Environment:
This project will be conducted under the mentorship of 4 well-funded investigators who will contribute their
complementary expertise in Geriatrics (Mark Lachs), Geriatric Cardiology (Mathew Maurer),
Implementation Science (Monika Safford), and N-of-1 trials (Ian Kronish). Advisors in deprescribing, shared
decision making, and biostatistics will provide additional content expertise to ensure the success of the
proposed project and catalyze my career development. This project will take place within the supportive
environment of Weill Cornell Medicine, which has demonstrated a deep commitment to my development as a
clinician-investigator for the past several years. Mentored Research Project: Despite its role as an integral part
of patient-centric and goal-concordant prescribing practice, deprescribing is seldom incorporated into clinical
practice due to several barriers. To improve patient-centered medication management, there is a need to
develop processes that can overcome these barriers. The objective of this proposal is to determine whether N-
of-1 trials—as a pragmatic patient-centered approach to medication optimization that can overcome key
barriers of deprescribing— can lead to increased patient confidence regarding the decision to continue or
discontinue a medication. To achieve this, I will: 1) determine key features of a feasible and pragmatic protocol
for deprescribing N-of-1 trials using a stakeholder-engaged iterative design approach; and 2) determine the
preliminary effectiveness of an adapted N-of-1 protocol on patient decision confidence and deprescribing, and
3) determine the facilitators and barriers of implementing an adapted N-of-1 protocol into real-world clinical
practice by conducting a type-1 hybrid effectiveness-implementation trial. I will achieve these aims by using ß-
blocker in heart failure with preserved ejection fraction (HFpEF) as a prototype for older adults with
multimorbidity and polypharmacy. This proposal will inform a future multicenter randomized controlled trial
focused on improving patient-reported outcomes, and provide a formative opportunity for me to obtain the
knowledge and skills necessary to become a leading researcher on patient-centered medication management.
项目总结
候选人:我的职业目标是改善患有多种慢性病的老年人的健康状况
通过制定和严格测试合理的策略来改善用药处方
并成为老年心脏病学的独立临床研究员和全国领先者。这
作为一名心力衰竭心脏病专家,这一领域对我来说特别相关,因为我关心的是几乎
普遍患有多种慢性病和多药并存。我作为这方面的新兴领导者的过往记录
该领域的证据是多份主要作者和资深作者的手稿,4名首席调查员获得赠款
包括GEMSSTAR,我作为威尔·康奈尔心力衰竭基金会主任的职位
老年保留性弹射(HFpEF)计划,以及我作为美国大学
心脏病学老年心脏病科早期职业专家工作组。导师和环境:
该项目将在4名资金雄厚的调查人员的指导下进行,他们将贡献他们的
老年医学(Mark Laches)、老年心脏病学(Mathew Maurer)、
实施科学(Monika Safford)和N-of-1试验(Ian Kronish)。取消处方的顾问,共享
决策和生物统计将提供更多的内容专门知识,以确保
提出的项目,并促进了我的职业发展。该项目将在支持性的
威尔·康奈尔医学院的环境,这表明了我作为一名
在过去的几年里,他一直是临床医生和研究员。指导性研究项目:尽管它是不可或缺的一部分
在以患者为中心和目标一致的处方实践中,取消处方很少被纳入临床
由于几个障碍的练习。为了改善以患者为中心的用药管理,有必要
制定能够克服这些障碍的流程。这项提案的目标是确定N-
Of-1试验-作为一种务实的以患者为中心的药物优化方法,可以克服关键
停药障碍--可增加患者对继续或继续开药的决定的信心
停止服药。为了实现这一目标,我将:1)确定一项可行和务实的议定书的关键特征
使用利益相关者参与的迭代设计方法取消N-of-1试验的处方;以及2)确定
调整后的N-of-1方案在患者决策信心和停药方面的初步有效性,以及
3)确定将经过调整的N-of-1方案应用于现实世界临床的促进者和障碍
通过进行第一类混合有效性-实施试验进行实践。我将通过使用??实现这些目标-
射血分数保留的心力衰竭阻滞剂(HFpEF)作为老年高血压患者的原型
多发病和多药联用。这项建议将为未来的多中心随机对照试验提供参考
专注于改善患者报告的结果,并为我提供了一个形成机会来获得
在以患者为中心的药物管理方面成为领先的研究人员所需的知识和技能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PARAG GOYAL其他文献
PARAG GOYAL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PARAG GOYAL', 18)}}的其他基金
Advancing the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
推进对话有助于提高疾病轨迹 (CHAT) 干预意识
- 批准号:
10668058 - 财政年份:2023
- 资助金额:
$ 23.64万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10045730 - 财政年份:2020
- 资助金额:
$ 23.64万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10433979 - 财政年份:2020
- 资助金额:
$ 23.64万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10673696 - 财政年份:2020
- 资助金额:
$ 23.64万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 23.64万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 23.64万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 23.64万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 23.64万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 23.64万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 23.64万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 23.64万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 23.64万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 23.64万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 23.64万 - 项目类别: